OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SDZ57

Sandoz Group AG

PharmaceuticalsVerified

Sandoz Group AG maintains a neutral capital structure with no dilution risk in the near term, as shares outstanding remain unchanged between basic and diluted counts at 432.7 million. However, liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents. This absence of liquidity data limits the ability to evaluate short-term financial flexibility. Profitability metrics are not available in the valuation snapshot, but the company operates in a sector where return on invested capital (ROIC) and operating margins are key performance indicators. Sandoz’s performance relative to industry medians for these metrics is currently indeterminate due to missing data. Geographically, Sandoz derives revenue from multiple regions, though the exact distribution is not disclosed in the available data. The company’s exposure to revenue concentration remains unquantified, which limits the ability to assess geographic risk. Growth trajectory is not explicitly quantified in the outlook, but analyst price targets suggest a wide range of expectations, from $36 to $81 per share, with a mean of $66.20 and median of $65.00. The mean recommendation of 2.53 indicates a slight bias toward "hold" or "buy" ratings, with 3 strong-buy and 4 buy recommendations. Risk factors include the inability to assess liquidity risk and the absence of detailed guidance on capital expenditures or R&D spending. Dilution risk is currently low, but the lack of balance-sheet inputs and forward-looking statements introduces uncertainty about the company’s financial resilience. Recent events include analyst estimates and price targets, but no specific filings or transcripts are cited in the available data. The absence of recent disclosures or strategic updates limits the ability to assess near-term operational or financial developments.

30-day price · SDZ(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanySandoz Group AG
TickerSDZ.S
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Sandoz Group AG is a global leader in generic pharmaceuticals and biosimilars, generating revenue primarily through the development, manufacturing, and distribution of off-patent medicines.

Classification. Sandoz is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with 92% confidence based on verified market data.

Sandoz Group AG maintains a neutral capital structure with no dilution risk in the near term, as shares outstanding remain unchanged between basic and diluted counts at 432.7 million. However, liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents. This absence of liquidity data limits the ability to evaluate short-term financial flexibility. Profitability metrics are not available in the valuation snapshot, but the company operates in a sector where return on invested capital (ROIC) and operating margins are key performance indicators. Sandoz’s performance relative to industry medians for these metrics is currently indeterminate due to missing data. Geographically, Sandoz derives revenue from multiple regions, though the exact distribution is not disclosed in the available data. The company’s exposure to revenue concentration remains unquantified, which limits the ability to assess geographic risk. Growth trajectory is not explicitly quantified in the outlook, but analyst price targets suggest a wide range of expectations, from $36 to $81 per share, with a mean of $66.20 and median of $65.00. The mean recommendation of 2.53 indicates a slight bias toward "hold" or "buy" ratings, with 3 strong-buy and 4 buy recommendations. Risk factors include the inability to assess liquidity risk and the absence of detailed guidance on capital expenditures or R&D spending. Dilution risk is currently low, but the lack of balance-sheet inputs and forward-looking statements introduces uncertainty about the company’s financial resilience. Recent events include analyst estimates and price targets, but no specific filings or transcripts are cited in the available data. The absence of recent disclosures or strategic updates limits the ability to assess near-term operational or financial developments.
Key takeaways
  • Sandoz Group AG has no immediate dilution risk, with basic and diluted shares outstanding aligned at 432.7 million.
  • Analysts exhibit a mixed outlook, with a mean recommendation of 2.53 and a wide range of price targets from $36 to $81.
  • Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • The company’s profitability and return metrics relative to industry medians are currently indeterminate due to missing valuation snapshot data.
  • Geographic revenue concentration and exposure to regional markets are not disclosed, limiting the ability to assess geographic risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$9.68B$1.39B$908.0M$1.02B
FY-3$9.31B$1.22B$848.0M$916.0M
FY-2$9.98B$365.0M$77.0M-$20.0M
FY-1$10.38B$318.0M$0.00-$318.0M
FY0$11.16B$1.41B$914.0M$339.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$17.54B$8.15B$40.0M
FY-3$17.56B$8.75B$74.0M
FY-2$19.43B$8.64B$1.11B
FY-1$19.91B$8.16B$1.19B
FY0$22.03B$9.38B$1.74B
PeriodOCFCapExFCFSBC
FY-4$1.35B-$416.0M$1.02B
FY-3$1.22B-$427.0M$916.0M
FY-2$362.0M-$625.0M-$20.0M
FY-1$656.0M-$596.0M-$318.0M
FY0$1.59B-$784.0M$339.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6$2.60B
FQ-5
FQ-4$2.48B
FQ-3
FQ-2$2.83B
FQ-1
FQ0$2.76B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricSDZActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Observations
IR observations
Mean price target66.20 USD
Median price target65.00 USD
High price target81.00 USD
Low price target36.00 USD
Mean recommendation2.53 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count4.00
Hold count8.00
Sell count2.00
Strong-sell count0.00
Mean EPS estimate4.03 USD
Last actual EPS3.64 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 06:32 UTC#ce6d047b
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 08:54 UTCJob: afe46abe